In line with these findings, next-generation sequencing (NGS) and expanded gene panels have improved diagnostic precision and differentiation of HCM from phenocopies like Fabry disease (GLA) and transthyretin cardiac amyloidosis (TTR). This evidence concerns the gene TTR and cardiac amyloidosis.